Geron Corporation (NASDAQ:GERN) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

Geron Corporation (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 21.30% and a negative net margin of 433.72%. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.38 million. During the same quarter last year, the company earned ($0.05) earnings per share. The firm’s revenue for the quarter was down 19.0% compared to the same quarter last year. On average, analysts expect Geron Corporation to post $-0.18 EPS for the current fiscal year and $-0.02 EPS for the next fiscal year.

Shares of Geron Corporation (GERN) traded up 6.553% during midday trading on Tuesday, reaching $2.195. The company had a trading volume of 4,565,175 shares. Geron Corporation has a 52 week low of $1.81 and a 52 week high of $3.15. The company’s market capitalization is $349.47 million. The company’s 50 day moving average price is $2.15 and its 200-day moving average price is $2.47.

Several equities research analysts have weighed in on the company. BidaskClub downgraded Geron Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research upgraded Geron Corporation from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Tuesday, October 3rd. Finally, FBR & Co restated a “buy” rating on shares of Geron Corporation in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.75.

TRADEMARK VIOLATION WARNING: “Geron Corporation (GERN) to Release Quarterly Earnings on Wednesday” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at

Geron Corporation Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Earnings History for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.